Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on December 15, 2021, to stockholders of record as of the close of business on November 24, 2021. Phibro is a global developer and supplier of animal health and mineral nutrition products, aimed at supporting livestock health and sustainability.
Phibro Animal Health Corporation (NASDAQ: PAHC) will release its first quarter financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for November 3, 2021, at 9:00 AM ET. Investors can access the presentation through the company’s investor relations website. This event is expected to provide key insights into the company's financial performance and future guidance, an important aspect for stakeholders.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 30th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2021, at 4:20 PM ET. Key executives, including Chairman Jack Bendheim, CFO Damian Finio, and EVP Daniel Bendheim, will address financial analysts and investors during the event. The live audio presentation will be accessible via the company's Investor Relations Website, with a replay available later.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported strong Q4 and full-year results for fiscal year 2021, with net sales of $220 million in Q4, up 19% year-over-year, and $833 million for the year, an increase of 4%. Net income surged to $17 million in Q4, reflecting a 203% increase, and $54 million for the year, a 62% rise. Diluted EPS also rose to $0.42 for Q4 and $1.34 for the full year. Guidance for FY 2022 projects net sales of $840-$870 million and net income of $45-$47 million.
Phibro Animal Health Corporation (Nasdaq: PAHC) will participate in the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 9:30 AM ET. Chairman and CEO Jack Bendheim, CFO Damian Finio, and EVP Daniel Bendheim will address analysts and investors during the session. The live audio presentation can be accessed on the company’s Investor Relations website, with a replay also available. Phibro focuses on developing a wide range of animal health and mineral nutrition products for livestock.
Phibro Animal Health Corporation (Nasdaq:PAHC) will participate in the Bank of America Virtual Global Healthcare Conference on September 15, 2021, at 9:10 AM ET. Chief Financial Officer Damian Finio will present to financial analysts and investors, with a live audio available on the company's Investor Relations website. A replay will also be archived for future access. Phibro is a global developer and supplier of animal health and nutrition products, helping produce healthy food sustainably.
Phibro Animal Health Corporation (Nasdaq:PAHC) will announce its fourth quarter and fiscal year 2021 financial results on August 25, 2021, post-market. A conference call will occur on August 26, 2021, at 9:00 AM ET, where interested parties can join via phone or webcast. The company focuses on developing and supplying animal health and mineral nutrition products for livestock, aiming to enhance food production while conserving natural resources. Further details are available on their investor website.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on September 22, 2021, to stockholders recorded on September 1, 2021. Phibro is a global developer, manufacturer, and supplier of animal health and mineral nutrition products aimed at enhancing food production efficiency while reducing resource use.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported Q3 FY2021 net sales of $212 million, a marginal increase of less than 1% year-over-year. Net income fell to $12 million, a decrease of 10%, with diluted EPS at $0.30, down by 9%. For the nine-month period, net sales reached $613 million, up slightly, while net income surged by 34% to $37 million. Adjusted EBITDA for Q3 declined by 7% to $28 million. The company received EU GMP approval for a new vaccine facility in Ireland and sees potential for a strong Q4. Financial guidance suggests Q4 net sales between $213-217 million.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 23, 2021, to shareholders on record as of June 2, 2021. Phibro Animal Health is a global developer and manufacturer of animal health and nutrition products aimed at promoting sustainable livestock production.